Issue 29

This week, MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced a partnership with self-help guru Deepak Chopra’s The Chopra Foundation, the first high-profile, celebrity-backed deal of its kind for a publicly traded psychedelics company.

While some investors weighed in on social media following the announcement praising the partnership as a boon to MindMed’s profile, others opined the affiliation will damage MindMed’s scientific and academic credibility in the eyes of institutional investors.

The discussion begs the question: will celebrity endorsement become commonplace in psychedelics brand strategy, and how will high-powered affiliation impact investments?

When it comes to psychedelics, global attitudes are shifting dramatically. In the Psychedelics as Medicine Report: Second Edition, PSYCH conducted a national representative survey to gauge awareness of and attitudes towards the potential use of psychedelics for the treatment of a variety of mental health conditions.

Roughly 45% of respondents reported knowing someone who they believed would benefit from psychedelic therapy and the majority agree more research needs to be done to understand the benefits/effects. This suggests more education is required to inform the wider public about psychedelics and to promote their use as valid, safe and effective alternatives to conventional medications.

Learn more about our approach and how attitudes are shifting in the report.